Alphamab Oncology Reports 2025 Interim Results and Business Highlights
SUZHOU, China, Aug. 29, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2025 and highlighted recent business progress. Financial Summary For the six months ended June 30, 2025, we recorded total revenue of RMB 319.44 million, an increase of 84.05% compared with the first half of 2024....
Mayapada Healthcare Holds Commencement Ceremony for an International Hospital in the Batam Tourism and International Healthcare SEZ
JAKARTA, Indonesia, Aug. 29, 2025 /PRNewswire/ -- Mayapada Healthcare (IDX:SRAJ), the healthcare services arm of Mayapada Group, held a commencement ceremony to mark the development of its international-standard hospital, Mayapada Apollo Batam International Hospital (MABIH), located in Batam Tourism and International Healthcare Special Economic Zone (SEZ), Sekupang, Batam, Riau Islands. The ceremony was led by the Chairman of Batam Indonesia Free Trade Zone Authority (BP Batam), Amsakar Achmad. The...
HEC Group and JungKwanJang Form Strategic Alliance to Drive a New Era in Eastern Tonic Health
SINGAPORE, Aug. 29, 2025 /PRNewswire/ -- The JungKwanJang delegation included Kim Yang-jin, Director General of the Overseas Business Division; Jung Jong, Director General of the Asia-Pacific Business Division; and Kim Jong-sik, Director of the Future Business Research Institute, along with five other representatives. HEC Group was represented by Director and General Manager Tang...
Everest Medicines Announces Interim Results for First Half of 2025
SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2025 along with a corporate update. "In the first half of 2025, Everest Medicines accelerated its transformation into a leading...
Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs
TOKYO, Aug. 28, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs). The collaboration aims to combine Celaid's proprietary platform of hematopoietic stem cell (HSC) expansion technology with AGC's iPSC technology to accelerate robust and scalable expansion of iPSC-HSPCs. In this...
Coventry Responds to Lapetus’s Secrecy Claim
Urges transparency on life expectancy accuracy Following Lapetus's imminent closure, argues elimination of any claim to trade secret protection TALLAHASSEE, Fla., Aug. 28, 2025 /PRNewswire/ -- Coventry First LLC ("Coventry"), the market leader in life settlements, this week filed a legal response opposing Lapetus Solutions, Inc.'s ("Lapetus") attempt to block disclosure of statutorily required life expectancy audit reports. The...
D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers
Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior treatment with platinum-based chemotherapy and anti-PD-(L)1 antibody but have not been previously treated with a KRAS G12C inhibitor Orphan Drug Designation was granted for...
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its board of directors (the "Board") has received a revised preliminary non-binding proposal letter (the...
Hua Medicine Announces 2025 Interim Results
Sales of HuaTangNing (华堂宁®) increased by 108% year-on-year, with net sales increasing by 112% year-on-year. Reimbursement coverage continued to expand, with a significant increase in prescription volumes across Tier 2 and Tier 3 hospitals, as our comprehensive commercialization strategy achieved significant results. Following the termination of the exclusive promotion service agreement with Bayer, the Company recognized a one-time...
WuXi Biologics’ Near-Term and Net-Zero Targets Approved by SBTi
Committed to net-zero across the value chain by 2050 Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, Aug. 28, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced its near-term and net-zero greenhouse gas (GHG)...
